Ashwagandha is probably the most studied adaptogen in clinical literature right now. A 2024 systematic review and meta-analysis covering multiple randomised controlled trials found statistically significant reductions in perceived stress scores compared to placebo. That's a meaningful signal. But the effect sizes vary considerably across trials, the mechanisms are still being mapped, and a lot of what's written about this plant online sits well ahead of what the data actually supports.
What the evidence actually shows
Let me start with the most rigorous recent synthesis. Arumugam et al. (2024) conducted a systematic review and meta-analysis of ashwagandha's effects on stress and anxiety, pooling data from multiple RCTs. The analysis found statistically significant reductions in perceived stress and anxiety measures across trials, with ashwagandha consistently outperforming placebo. The effect sizes were real — but moderate, not dramatic. That distinction matters.
One of the most-cited individual trials is Chandrasekhar et al. (2013), a double-blind, placebo-controlled RCT in 64 adults with a history of chronic stress. Participants receiving 300mg of a full-spectrum root extract twice daily for 60 days showed statistically significant reductions in scores on the Perceived Stress Scale and serum cortisol levels compared to placebo (p < 0.001). The cortisol reduction in the treatment group was approximately 27.9% versus 7.9% in the placebo group. That's a notable gap.
Salve et al. (2020) ran a similar 60-day RCT in 60 healthy adults under chronic stress, using 240mg of a standardised extract. They found significant reductions in cortisol, stress scores, and self-reported sleep quality in the ashwagandha group versus placebo. The sample sizes here are small enough that I'd want to see replication in larger cohorts before drawing firm conclusions — but the direction of effect is consistent across trials, which counts for something.
My honest read: ashwagandha has a reasonably coherent body of evidence for stress-related outcomes. It's not conclusive by pharmaceutical standards, but for a botanical, the RCT quality is better than most. If you're researching nootropic supplement UK options, ashwagandha is one of the few where I can point you to actual controlled trials rather than just mechanistic speculation.
The biology: what's happening at a cellular level
Ashwagandha belongs to the Solanaceae family. Its primary bioactive constituents are withanolides — steroidal lactones concentrated in the root — alongside alkaloids and saponins. The withanolides are where most of the research attention sits.
The proposed mechanisms are multiple and still being clarified. Speers et al. (2021) describe several pathways: modulation of the hypothalamic-pituitary-adrenal (HPA) axis, which governs the stress response and cortisol output; interaction with GABAergic signalling, which may account for the anxiolytic-type effects observed in trials; and some evidence of influence on heat shock proteins, which are involved in cellular stress responses.
There's also a neuroinflammatory angle. Wróbel-Biedrawa et al. (2024) reviewed the anti-neuroinflammatory properties of several adaptogens including ashwagandha, noting that withanolides may modulate NF-κB signalling — a key pathway in inflammatory cascades in the central nervous system. The data here is largely preclinical, so I'd be cautious about overstating it. Animal studies suggest a meaningful effect; whether that translates cleanly to human cognition at typical supplemental doses is a different question.
Wiciński et al. (2024) add another layer: ashwagandha may influence lipid metabolism and vascular endothelial function, and some evidence points to effects on thyroid hormone levels. These are interesting signals, and they also illustrate why blanket claims about ashwagandha "doing X" are usually too simple. It appears to work across several systems simultaneously, which is characteristic of adaptogenic compounds generally.
The term "adaptogen" itself is worth unpacking. It was coined in Soviet pharmacology in the 1940s to describe substances that may help the body maintain physiological equilibrium under stress — not by sedating, not by stimulating, but by supporting regulatory balance. Whether that concept holds up mechanistically across all claimed adaptogens is debatable. For ashwagandha specifically, the HPA axis modulation data gives it a reasonably plausible biological basis.
Dosing: what the clinical trials actually used
This is where a lot of supplement marketing goes wrong. Doses in trials range from 240mg to 600mg of standardised root extract per day, typically split across one or two doses. The 300mg twice-daily protocol used in Chandrasekhar et al. (2013) is one of the more replicated approaches. Salve et al. (2020) used 240mg once daily and still observed significant effects.
Standardisation matters enormously. Most trials use extracts standardised to a specific withanolide content — typically 2.5% to 5%. A product that lists "ashwagandha root powder" without specifying withanolide concentration is giving you very little useful information. The raw powder and a standardised extract are not equivalent.
Duration also matters. Most trials ran for 8 to 12 weeks. Shorter periods tend to show weaker or inconsistent effects. If you're trialling ashwagandha and expecting to notice something in a fortnight, you're probably working against the research timeline.
Ashwagandha isn't something I've included in the KōJō Daily Formula — the formula focuses on a different set of evidence-backed ingredients including creatine monohydrate, Vitamin C, and glycine — but understanding what the dosing literature says about ashwagandha is directly relevant if you're considering adding it separately. The clinical doses are achievable from quality single-ingredient products; just check the standardisation on the label.
Ashwagandha and cognitive performance specifically
This is where I want to be precise, because the cognitive claims floating around online often run ahead of the evidence.
Most of ashwagandha's cognitive data is indirect — stress and cortisol reduction may support cognitive function, because chronic stress is genuinely disruptive to memory, attention, and executive function. That's a plausible chain of reasoning. But it's not the same as direct nootropic action.
Mikulska et al. (2023) reviewed the current evidence on ashwagandha's health-related activities and noted some trial data suggesting possible effects on memory and cognitive task performance, but characterised the evidence as preliminary. The trials measuring cognitive outcomes directly tend to be small, use heterogeneous populations, and measure different cognitive domains — making it hard to draw a clean conclusion.
Majeed et al. (2023) studied a standardised ashwagandha root extract in healthy adults over 90 days, finding significant improvements in stress and anxiety scores alongside self-reported quality of life measures. The study also noted modulation of certain biomarkers. Again, the sample was relatively small, and quality of life is a composite measure — useful but broad.
If you're specifically interested in the cognitive supplement field more broadly, I've written about this in more depth in the cognitive supplement UK piece. The short version: ashwagandha's cognitive case is strongest when framed as stress-pathway support rather than direct nootropic action.
The cortisol connection
Cortisol is central to understanding why ashwagandha research focuses so heavily on stress. It's the primary glucocorticoid released during the stress response — essential in acute situations, potentially problematic when chronically elevated. Sustained high cortisol has been associated in the research literature with disrupted sleep architecture, impaired memory consolidation, and attentional difficulties.
The cortisol data from ashwagandha trials is some of the more objective signal in this space. The Chandrasekhar 2013 trial measured serum cortisol directly and found a significant reduction in the treatment group. Arumugam et al. (2024) confirmed this pattern across multiple trials in their meta-analysis.
What I find interesting is the timing dimension. If you're someone who experiences cortisol spikes at night — which disrupts sleep and by extension everything downstream — the HPA-modulating properties of ashwagandha are at least mechanistically relevant. I wouldn't overstate it, but it's a coherent rationale for evening dosing in some protocols.
What "adaptogen" actually means — and what it doesn't
The word gets used loosely. In popular usage, "adaptogen" has become a marketing category that includes everything from ashwagandha to mushroom extracts to obscure Siberian herbs. That's not particularly useful.
The original pharmacological definition required three criteria: low toxicity at normal doses, non-specific action (affecting multiple systems rather than one), and a normalising effect on physiological function regardless of the direction of stress. Ashwagandha meets these criteria more convincingly than most plants given the label.
Mandlik et al. (2021) reviewed the pharmacological evidence and safety profile in depth, noting that ashwagandha has a well-characterised toxicity profile at typical doses, with adverse events in trials generally mild and comparable to placebo. That's relevant context — it's not a zero-risk compound, but the risk profile at studied doses appears reasonable.
Sprengel et al. (2025) provide a useful recent overview of mechanisms and applications, noting that ashwagandha's multi-system effects — on the HPA axis, thyroid, and inflammatory pathways — are consistent with the adaptogenic model, while also acknowledging that the precise mechanisms remain under investigation.
Safety and what to watch for
Verma et al. (2021) ran a dedicated safety-focused RCT in healthy volunteers, finding no clinically significant adverse effects at 300mg twice daily over 8 weeks. Liver enzyme levels, haematological markers, and vital signs remained within normal ranges. That's reassuring, though it doesn't mean everyone will tolerate it identically.
There are populations where caution is warranted. Ashwagandha may influence thyroid hormone levels — relevant for anyone with thyroid conditions or on thyroid medication. Some evidence suggests it may affect testosterone and reproductive hormones, which matters depending on your situation. Pregnancy is generally considered a contraindication based on traditional use data and some animal studies. And rare cases of liver injury have been reported in the literature, though causality is difficult to establish in case reports.
None of this makes ashwagandha dangerous at typical doses for healthy adults. But "generally well-tolerated in trials" is not the same as "safe for everyone in all circumstances." If you're on medication or have an existing condition, talk to your GP before adding it.
Frequently asked questions
How long does ashwagandha take to have a noticeable effect?
Most clinical trials run for 8 to 12 weeks, and that's the timeframe where consistent effects on stress and cortisol measures tend to emerge. Expecting significant changes in two or three weeks isn't well-supported by the trial data. Chandrasekhar et al. (2013) used a 60-day protocol and found significant results at endpoint — not at earlier interim measures.
What dose of ashwagandha is supported by clinical evidence?
Trials have used between 240mg and 600mg of standardised root extract daily, typically split into one or two doses. Salve et al. (2020) found significant effects at 240mg once daily. The extract should be standardised to withanolide content — raw powder without standardisation is not directly comparable to what was studied in trials.
Is ashwagandha safe to take long-term?
The longest well-controlled trials run to around 90 days. Within that window, Verma et al. (2021) found no clinically significant adverse effects in healthy volunteers. Data beyond 12 weeks is limited, and rare case reports of liver injury exist in the wider literature. Periodic breaks and GP oversight seem sensible for longer-term use.
Does ashwagandha directly improve memory or focus?
The direct cognitive evidence is limited and preliminary. Some trials report improvements in cognitive task performance, but the most consistent data is on stress and cortisol outcomes. Mikulska et al. (2023) characterise the cognitive evidence as emerging rather than established. The cognitive rationale is largely mediated through stress-pathway effects rather than direct nootropic action.
Can ashwagandha be combined with other supplements?
Most trials study ashwagandha in isolation, so combination data is sparse. There are no well-documented dangerous interactions with common supplements at standard doses, but ashwagandha may affect thyroid hormone levels and sedative pathways, so combinations with thyroid medication or sedatives warrant medical supervision. Mandlik et al. (2021) cover the known pharmacological interactions in some depth.
Does ashwagandha affect physical performance as well as stress?
There's a separate body of evidence on physical performance. Bonilla et al. (2024) conducted a systematic review and Bayesian meta-analysis finding that ashwagandha supplementation may support muscular strength and recovery outcomes, though effect sizes were modest and the authors noted significant heterogeneity across trials. It's a real signal, but not a large one.
My honest take
I've spent a fair amount of time in this literature, and ashwagandha is one of the few botanicals where I don't feel embarrassed pointing people toward the research. The RCT quality is better than most. The cortisol and stress data is reasonably consistent. The safety profile at studied doses looks acceptable.
But I also notice how quickly the marketing runs ahead of the science. "Cognitive performance" is a broad claim that the evidence doesn't fully support in the direct sense. What the data shows more clearly is an effect on the stress response — and if chronic stress is genuinely affecting your cognition, then addressing that pathway may help. That's a legitimate but indirect argument.
I'm also honest with myself that the trials are mostly short, mostly small, and often funded by ingredient manufacturers. That doesn't invalidate them — but it does mean I hold the conclusions with appropriate scepticism rather than treating them as settled.
If you're a healthy adult under genuine chronic stress, the evidence is reasonable enough that ashwagandha is worth considering at a properly standardised dose. If you're hoping it'll sharpen your focus the way a good night's sleep does, you're probably expecting more than the data supports. The effect is real. It's just more modest and more indirect than the marketing tends to suggest.
That honesty is why I built KōJō the way I did. Not every ingredient that has a plausible mechanism deserves to be in a daily formula. And not every botanical with a cultural history of use has the RCT data to back it up at the doses and forms being sold. Ashwagandha sits in an interesting middle ground — better evidenced than most, but still with meaningful gaps I wouldn't paper over.
This article is for informational purposes only and does not constitute medical advice. Consult your healthcare provider before starting any supplement regimen.
References (11 studies)
- Arumugam et al. (2024) — Effects of Ashwagandha (Withania somnifera) on stress and anxiety: A systematic review and meta-analysis. PMID 39348746.
- Chandrasekhar et al. (2013) — A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of Ashwagandha root. PMID 23439798.
- Salve et al. (2020) — Adaptogenic and Anxiolytic Effects of Ashwagandha Root Extract in Healthy Adults: A Double-blind, Randomized, Placebo-controlled Clinical Study. PMID 32021735.
- Speers et al. (2021) — Effects of Withania somnifera (Ashwagandha) on Stress and the Stress-Related Neuropsychiatric Disorders Anxiety, Depression, and Insomnia. PMID 34254920.
- Wróbel-Biedrawa et al. (2024) — Anti-Neuroinflammatory Effects of Adaptogens: A Mini-Review. PMID 38398618.
- Wiciński et al. (2024) — Ashwagandha's Multifaceted Effects on Human Health: Impact on Vascular Endothelium, Inflammation, Lipid Metabolism, and Beyond. PMID 39125360.
- Mikulska et al. (2023) — Ashwagandha (Withania somnifera) — Current Research on the Health-Promoting Activities: A Narrative Review. PMID 37111543.
- Majeed et al. (2023) — A standardized Ashwagandha root extract alleviates stress, anxiety, and improves quality of life in healthy adults by modulating stress hormones. PMID 37832082.
- Mandlik et al. (2021) — Pharmacological evaluation of Ashwagandha highlighting its healthcare claims, safety, and toxicity aspects. PMID 32242751.
- Verma et al. (2021) — Safety of Ashwagandha Root Extract: A Randomized, Placebo-Controlled, study in Healthy Volunteers. PMID 33338583.
- Bonilla et al. (2024) — Effects of Ashwagandha (Withania somnifera) on Physical Performance: Systematic Review and Bayesian Meta-Analysis. PMID 33670194.
